Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors

Receptor activator of nuclear factor-κB ligand (RANKL) has been actively pursued as a therapeutic target for osteoporosis, given that RANKL is the master mediator of bone resorption as it promotes osteoclast differentiation, activity and survival. We employed a structure-based virtual screening appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinotas, Vagelis, Liepouri, Fotini, Ouzouni, Maria-Dimitra, Chalkidi, Niki, Papaneophytou, Christos, Lampropoulou, Mariza, Vidali, Veroniki P., Kontopidis, George, Couladouros, Elias, Eliopoulos, Elias, Papakyriakou, Athanasios, Douni, Eleni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379842/
https://www.ncbi.nlm.nih.gov/pubmed/37511048
http://dx.doi.org/10.3390/ijms241411290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379842/
https://www.ncbi.nlm.nih.gov/pubmed/37511048
http://dx.doi.org/10.3390/ijms241411290

Ejemplares similares